The Motley Foolยท2025-04-23 09:50Core Insights - Novo Nordisk has faced challenges over the past year, with financial results not meeting investor expectations despite strong performance relative to peers [1] - The company is experiencing increased competition from Eli Lilly, particularly in the GLP-1 diabetes and obesity drug markets [2] Group 1: Financial Performance - In 2024, Novo Nordisk's revenue increased by 25% year over year to 290 billion Danish kroner ($44.7 billion) [2] - The company held a 55.1% share of the GLP-1 diabetes market as of November, a slight increase from 54.8% in the previous year [2] Group 2: Competitive Landscape - Eli Lilly reported positive phase 3 results for orforglipron, a daily oral GLP-1 therapy, which could attract patients preferring oral medication over injections [3][4] - Orforglipron demonstrated efficacy in reducing A1C levels by 1.3% to 1.6% and achieving a mean weight loss of 7.3 kilograms (16 pounds) over 40 weeks, comparable to Novo Nordisk's Ozempic [5] Group 3: Pipeline and Future Prospects - Novo Nordisk has several oral weight loss and diabetes candidates in its pipeline, including amycretin, which showed promising early-stage results with a mean weight reduction of 13.1% after 12 weeks [6][7] - The company is also exploring label expansions for existing medicines and developing new candidates for conditions like Alzheimer's disease and blood disorders [8] - Novo Nordisk is expected to maintain its leadership in diabetes and weight loss markets while achieving strong financial results and returns for long-term investors [9]